Local Intracoronary Fibrinolysis in Acute Myocardial Infarction of Ectatic Coronary Arteries in the Post-Abciximab Era

Cardiovasc Revasc Med. 2021 Nov:32:69-74. doi: 10.1016/j.carrev.2021.01.005. Epub 2021 Jan 14.

Abstract

Percutaneous intervention in the context of coronary artery ectasia (CAE) is penalized with no-reflow phenomenon. The glycoprotein-IIb/IIIa-inhibitor abciximab was the most accepted method for pharmacology thrombus resolution in this scenario, nevertheless, this agent was recently withdrawn. We describe 5 patients treated with local intracoronary fibrinolysis administrated through predesigned catheters in the setting of AMI and CAE.

Keywords: Coronary artery ectasia; Intracoronary fibrinolysis; No-reflow phenomenon.

Publication types

  • Review

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal
  • Coronary Vessels* / diagnostic imaging
  • Coronary Vessels* / surgery
  • Fibrinolysis
  • Humans
  • Immunoglobulin Fab Fragments
  • Myocardial Infarction* / drug therapy
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab